অনুসন্ধান ফলাফলগুলি - Kee‐Young Shin
- প্রদর্শন 1 - 2 ফলাফল এর 2
-
1
Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge অনুযায়ী Tingting Qin, Austin K. Mattox, Jean S. Campbell, Jong Chul Park, Kee-Young Shin, Shiting Li, Peter M. Sadow, William C. Faquin, Goran Micevic, Andrew J. Daniels, Robert I. Haddad, Christopher Garris, Mikaël J. Pittet, Thorsten R. Mempel, Anne O’Neill, Maureen A. Sartor, Sara I. Pai
প্রকাশিত 2025Artigo -
2
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck অনুযায়ী Glenn J. Hanna, Anne O’Neill, Kee‐Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K.V. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad
প্রকাশিত 2021Artigo
অনুসন্ধান সাধনীগুলি:
সম্পর্কিত বিষয়
Head and neck
Immunotherapy
Internal medicine
Medicine
Oncology
Surgery
Adjuvant
Astrobiology
Basal cell
Biochemistry
Biology
Cancer
Cancer research
Chemotherapy
DNA methylation
Epigenetic therapy
Epigenetics
Gene
Gene expression
Head and neck cancer
Head and neck squamous-cell carcinoma
Immune system
Immunology
Nivolumab
Radiation therapy
Refractory (planetary science)